Cargando…

An ayurvedic perspective along with in silico study of the drugs for the management of SARS-CoV-2

BACKGROUND: COVID-19 is the disease caused by SARS-CoV2, it was identified in Wuhan, China, in 2019. It then extended across the globe and was termed as a pandemic in 2020. Though research work on its vaccine and drugs are carried out across the globe, it is even necessary to look over it through al...

Descripción completa

Detalles Bibliográficos
Autores principales: Gandhi, Abhay Jayprakash, Rupareliya, Jalpa Deepak, Shukla, V.J., Donga, Shilpa B., Acharya, Rabinarayan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. on behalf of Institute of Transdisciplinary Health Sciences and Technology and World Ayurveda Foundation. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373022/
https://www.ncbi.nlm.nih.gov/pubmed/32837100
http://dx.doi.org/10.1016/j.jaim.2020.07.002
_version_ 1783561426344869888
author Gandhi, Abhay Jayprakash
Rupareliya, Jalpa Deepak
Shukla, V.J.
Donga, Shilpa B.
Acharya, Rabinarayan
author_facet Gandhi, Abhay Jayprakash
Rupareliya, Jalpa Deepak
Shukla, V.J.
Donga, Shilpa B.
Acharya, Rabinarayan
author_sort Gandhi, Abhay Jayprakash
collection PubMed
description BACKGROUND: COVID-19 is the disease caused by SARS-CoV2, it was identified in Wuhan, China, in 2019. It then extended across the globe and was termed as a pandemic in 2020. Though research work on its vaccine and drugs are carried out across the globe, it is even necessary to look over it through alternative sciences. OBJECTIVE: The objective of this study is to look over the disease through Ayurvedic perspective, analyse possible pathologies, select appropriate drugs and to study in-silico screening on these selected drugs. MATERIALS & METHODS: Available symptoms of COVID-19 were thoroughly studied and reviewed through Ayurveda classics, internet, preprints, etc. to understand the nature of the disease with the Ayurvedic perspective. The molecular Docking and Grid were generated through Pyrx Software with Autodock. The Lipinski Rule of Five data generated from Swiss ADME software and Target prediction of selected phytoconstituents were done by Swiss target prediction. RESULTS: In Ayurveda, COVID-19 can be considered as Janapadaudhwans, Vata-Kaphaja Sannipatika Jwara, Aupasargika Vyadhi, and Dhatupaka Awastha. In the molecular docking study, the binding energy and inhibition of 6 Gingesulphonic acid from Zingiber officinalis (Sunthi) is greater than hydroxychloroquine and quinine. Most of the selected phytoconstituents follow the Lipinski rule of five. Target prediction of selected phytoconstituents was done on target of SARS-CoV-2, humoral immunity, and antiviral activity. Every selected phytoconstituents works on minimum one of the targets. CONCLUSION: Thus, from the above results obtained from reviewing Ayurveda classics and after the virtual screening of selected drugs we can conclude that Nagaradi Kashaya (Sunthi, Puskarmoola, Kantakari, Guduchi) may have appreciable results in combating SARS-CoV-2. Thus, Nagaradi Kashayam, a classical formulation can be a trial candidate for conducting further clinical trial.
format Online
Article
Text
id pubmed-7373022
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Authors. Published by Elsevier B.V. on behalf of Institute of Transdisciplinary Health Sciences and Technology and World Ayurveda Foundation.
record_format MEDLINE/PubMed
spelling pubmed-73730222020-07-22 An ayurvedic perspective along with in silico study of the drugs for the management of SARS-CoV-2 Gandhi, Abhay Jayprakash Rupareliya, Jalpa Deepak Shukla, V.J. Donga, Shilpa B. Acharya, Rabinarayan J Ayurveda Integr Med Original Research Article (Experimental) BACKGROUND: COVID-19 is the disease caused by SARS-CoV2, it was identified in Wuhan, China, in 2019. It then extended across the globe and was termed as a pandemic in 2020. Though research work on its vaccine and drugs are carried out across the globe, it is even necessary to look over it through alternative sciences. OBJECTIVE: The objective of this study is to look over the disease through Ayurvedic perspective, analyse possible pathologies, select appropriate drugs and to study in-silico screening on these selected drugs. MATERIALS & METHODS: Available symptoms of COVID-19 were thoroughly studied and reviewed through Ayurveda classics, internet, preprints, etc. to understand the nature of the disease with the Ayurvedic perspective. The molecular Docking and Grid were generated through Pyrx Software with Autodock. The Lipinski Rule of Five data generated from Swiss ADME software and Target prediction of selected phytoconstituents were done by Swiss target prediction. RESULTS: In Ayurveda, COVID-19 can be considered as Janapadaudhwans, Vata-Kaphaja Sannipatika Jwara, Aupasargika Vyadhi, and Dhatupaka Awastha. In the molecular docking study, the binding energy and inhibition of 6 Gingesulphonic acid from Zingiber officinalis (Sunthi) is greater than hydroxychloroquine and quinine. Most of the selected phytoconstituents follow the Lipinski rule of five. Target prediction of selected phytoconstituents was done on target of SARS-CoV-2, humoral immunity, and antiviral activity. Every selected phytoconstituents works on minimum one of the targets. CONCLUSION: Thus, from the above results obtained from reviewing Ayurveda classics and after the virtual screening of selected drugs we can conclude that Nagaradi Kashaya (Sunthi, Puskarmoola, Kantakari, Guduchi) may have appreciable results in combating SARS-CoV-2. Thus, Nagaradi Kashayam, a classical formulation can be a trial candidate for conducting further clinical trial. The Authors. Published by Elsevier B.V. on behalf of Institute of Transdisciplinary Health Sciences and Technology and World Ayurveda Foundation. 2022 2020-07-21 /pmc/articles/PMC7373022/ /pubmed/32837100 http://dx.doi.org/10.1016/j.jaim.2020.07.002 Text en © 2020 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Research Article (Experimental)
Gandhi, Abhay Jayprakash
Rupareliya, Jalpa Deepak
Shukla, V.J.
Donga, Shilpa B.
Acharya, Rabinarayan
An ayurvedic perspective along with in silico study of the drugs for the management of SARS-CoV-2
title An ayurvedic perspective along with in silico study of the drugs for the management of SARS-CoV-2
title_full An ayurvedic perspective along with in silico study of the drugs for the management of SARS-CoV-2
title_fullStr An ayurvedic perspective along with in silico study of the drugs for the management of SARS-CoV-2
title_full_unstemmed An ayurvedic perspective along with in silico study of the drugs for the management of SARS-CoV-2
title_short An ayurvedic perspective along with in silico study of the drugs for the management of SARS-CoV-2
title_sort ayurvedic perspective along with in silico study of the drugs for the management of sars-cov-2
topic Original Research Article (Experimental)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373022/
https://www.ncbi.nlm.nih.gov/pubmed/32837100
http://dx.doi.org/10.1016/j.jaim.2020.07.002
work_keys_str_mv AT gandhiabhayjayprakash anayurvedicperspectivealongwithinsilicostudyofthedrugsforthemanagementofsarscov2
AT rupareliyajalpadeepak anayurvedicperspectivealongwithinsilicostudyofthedrugsforthemanagementofsarscov2
AT shuklavj anayurvedicperspectivealongwithinsilicostudyofthedrugsforthemanagementofsarscov2
AT dongashilpab anayurvedicperspectivealongwithinsilicostudyofthedrugsforthemanagementofsarscov2
AT acharyarabinarayan anayurvedicperspectivealongwithinsilicostudyofthedrugsforthemanagementofsarscov2
AT gandhiabhayjayprakash ayurvedicperspectivealongwithinsilicostudyofthedrugsforthemanagementofsarscov2
AT rupareliyajalpadeepak ayurvedicperspectivealongwithinsilicostudyofthedrugsforthemanagementofsarscov2
AT shuklavj ayurvedicperspectivealongwithinsilicostudyofthedrugsforthemanagementofsarscov2
AT dongashilpab ayurvedicperspectivealongwithinsilicostudyofthedrugsforthemanagementofsarscov2
AT acharyarabinarayan ayurvedicperspectivealongwithinsilicostudyofthedrugsforthemanagementofsarscov2